A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Mevociclib (Primary) ; Carboplatin; Fulvestrant
- Indications Advanced breast cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Syros Pharmaceuticals
- 05 Mar 2021 Status changed from active, no longer recruiting to discontinued.
- 06 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 17 Oct 2019 Results from expansion portion of the trial published in Syros Pharmaceuticals Media Release